Keywords
Urology ×
Eligibility Determination ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

336 Search results.

Eligibility Polycystic Kidney Disease NCT01873235

- 1/21/21 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
PKD Clinical and Translational Core Study; ODM derived from: https://clinicaltrials.gov/show/NCT01873235

Eligibility Low Risk Prostate Cancer NCT01877070

- 7/6/20 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Decision Making in Men With Early Stage Prostate Cancer Patients and Partners/Close Allies; ODM derived from: https://clinicaltrials.gov/show/NCT01877070

Eligibility Low Grade Prostate Cancer NCT01192438

- 7/6/20 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Laser Based Focal Ablation of Low Grade Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01192438

Eligibility Localized Prostate Cancer NCT01931046

- 7/2/20 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of a Recombinant Adenovirus to Treat Localized Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01931046

Eligibility Localized Prostate Cancer NCT01902680

- 7/1/20 - 1 form, 2 itemgroups, 29 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Phase II Study of Feasibility of Focal Therapy for Prostate Cancer of Good Prognosis With Permanent I125 Localized Implant.; ODM derived from: https://clinicaltrials.gov/show/NCT01902680

Eligibility Hormone-resistant Prostate Cancer NCT02169063

- 6/7/20 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Carbon-11 Acetate and Fluorine F 18 Sodium Fluoride PET as a Biomarker of Treatment Response in Patients With Hormone Resistant Metastatic Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02169063

Eligibility High-risk Prostate Cancer NCT01488968

- 6/6/20 - 1 form, 1 itemgroup, 10 items, 1 language
Itemgroup: Inclusion Criteria
Conventional Versus Hypofractionated Radiation in High Risk Prostate Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01488968

Eligibility Hormone-refractory Prostate Cancer NCT01422850

- 5/20/20 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Safety Study of Repeated Dosing of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT01422850

Eligibility Hormone Refractory Prostate Cancer NCT02208583

- 5/19/20 - 1 form, 2 itemgroups, 25 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Molecular Phenotype Changes and Personalized Treatment for CRPC; ODM derived from: https://clinicaltrials.gov/show/NCT02208583

Eligibility Prostate Cancer NCT02375035

- 4/19/20 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Developing a Safer and More Accurate Device for Biopsies of Suspected Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02375035

Eligibility Hormone Refractory Prostate Cancer NCT00928252

- 3/1/20 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00928252

Eligibility Hormone Refractory Prostate Cancer NCT01741116

- 3/1/20 - 1 form, 2 itemgroups, 19 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01741116